会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Monoclonal antibodies and methods for their use in the detection of cervical disease
    • 单克隆抗体及其用于检测宫颈疾病的方法
    • US08076093B2
    • 2011-12-13
    • US12545738
    • 2009-08-21
    • Douglas P. MalinowskiTimothy J. FischerAdriann J. Taylor
    • Douglas P. MalinowskiTimothy J. FischerAdriann J. Taylor
    • G01N33/53
    • G01N33/57411C07K14/4738C07K16/3069C07K2317/34
    • Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM2. Monoclonal antibodies having the binding characteristics of an MCM2 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM2 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM2 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM2 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
    • 提供用于诊断患者样本中高级宫颈疾病的组成和方法。 组合物包括与MCM2特异性结合的新单克隆抗体及其变体和片段。 还提供具有本发明的MCM2抗体的结合特征的单克隆抗体。 产生本发明的MCM2单克隆抗体的杂交瘤细胞系也在本文中公开。 该组合物用于诊断高级宫颈疾病的实践方法,包括检测来自患者的子宫颈样品中MCM2的过表达。 还提供了用于实施本发明的方法的试剂盒。 包含MCM2表位的氨基酸序列的多肽和在产生抗体中使用这些多肽的方法也包括在本发明中。
    • 8. 发明申请
    • NUCLEIC ACID-BASED METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER
    • 基于核酸的方法和组合物检测卵巢癌
    • US20090087849A1
    • 2009-04-02
    • US12205464
    • 2008-09-05
    • Douglas P. MalinowskiTimothy J. FischerJohn W. Groelke
    • Douglas P. MalinowskiTimothy J. FischerJohn W. Groelke
    • C12Q1/68
    • C12Q1/6886C12Q2600/112C12Q2600/158
    • Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression or underexpression of at least one nucleic acid biomarker in a body sample, wherein the biomarker is selectively overexpressed or underexpressed in ovarian cancer. The body sample may be, for example, an ovarian tissue sample. The biomarkers of the invention include any nucleic acid molecule that is selectively overexpressed in ovarian cancer, including, for example, MMP-7, PAEP, CA125, HE4, PLAUR, MUC-1, SLPI, SSP1, MSLN, SPON1, interleukin-7, folate receptor 1, claudin 3, inhibin A, inhibin BB, inhibin BA, and PAI-1. Overexpression or underexpression of a biomarker of interest is detected at the nucleic acid level using such methods as real-time PCR and various nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.
    • 提供了用于鉴定患者样品中卵巢癌的方法和组合物。 本发明的方法包括检测身体样品中至少一种核酸生物标志物的过表达或低表达,其中所述生物标志物在卵巢癌中选择性地过表达或低表达。 身体样品可以是例如卵巢组织样品。 本发明的生物标志物包括在卵巢癌中选择性过表达的任何核酸分子,包括例如MMP-7,PAEP,CA125,HE4,PLAUR,MUC-1,SLPI,SSP1,MSLN,SPON1,白介素-7 ,叶酸受体1,紧密连蛋白3,抑制素A,抑制素BB,抑制素BA和PAI-1。 使用实时PCR和各种核酸杂交技术的方法,在核酸水平检测感兴趣的生物标志物的过表达或低表达。 还提供了用于实施本发明的方法的试剂盒。